Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benefit from treatment with tetracyclines in the prevention of skin toxicity of cetuximab in association with an intensified FOLFIRI regimen in patients with metastatic colorectal cancer in first or second line therapy. Open, multicenter, randomized, phase III study. [Intérêt d'un traitement par cyclines dans la prévention de la toxicité cutanée du Cétuximab lors de son association à un FOLFIRI intensifié chez des patients avec un cancer colorectal en première ou deuxième ligne métastatique. Etude ouverte, multicentrique, randomisée, de phase III.]

X
Trial Profile

Benefit from treatment with tetracyclines in the prevention of skin toxicity of cetuximab in association with an intensified FOLFIRI regimen in patients with metastatic colorectal cancer in first or second line therapy. Open, multicenter, randomized, phase III study. [Intérêt d'un traitement par cyclines dans la prévention de la toxicité cutanée du Cétuximab lors de son association à un FOLFIRI intensifié chez des patients avec un cancer colorectal en première ou deuxième ligne métastatique. Etude ouverte, multicentrique, randomisée, de phase III.]

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxycycline (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Bacterial infections; Colorectal cancer; Skin disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SKINUX
  • Most Recent Events

    • 25 Mar 2020 Biomarkers information updated
    • 02 Jul 2012 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top